19:01:56 Europe / Stockholm

Bifogade filer

Kurs & Likviditet

Kursutveckling och likviditet under dagen för detta pressmeddelande

Beskrivning

LandDanmark
ListaSpotlight DK
SektorHälsovård
IndustriLäkemedel & Handel
DanCann Pharma grundades 2018 och är ett danskt läkemedelsbioteknikbolag som drivs av cannabinoider. DanCann Pharma fokuserar på att upptäcka, utveckla, tillverka och kommersialisera nya cannabinoida läkemedel inom ett brett spektrum av sjukdomsområden. Bolaget tillverkar och distribuerar receptbelagda läkemedel och receptfria läkemedel (OTC), främst fokuserade på smärtpatienter med alternativa behov och hantering av sin sjukdom, täckta av det danska pilotprogrammet för medicinsk cannabis.

Kalender

2022-04-07 Årsstämma 2022
2022-02-25 Bokslutskommuniké 2021
2021-11-26 Kvartalsrapport 2021-Q3
2021-08-27 Kvartalsrapport 2021-Q2
2021-07-23 Extra Bolagsstämma 2021
2021-05-28 Kvartalsrapport 2021-Q1
2021-04-29 Ordinarie utdelning DANCAN 0.00 DKK
2021-04-28 Årsstämma 2021
2021-02-26 Bokslutskommuniké 2020
2021-07-23 16:00:00

MINUTES OF EXTRAORDINARY GENERAL MEETING
held in Dancann Pharma A/S, business reg. no. 39 42 60 05

On 23 July 2021 at 14:00 pm (CET), an extraordinary general meeting was held in the Company at the registered office of the Company, Rugvænget 5, DK-6823 Ansager, Denmark. The agenda was as follows:

1. Proposed resolution to increase the share capital of the Company through cash contribution without pre-emption rights for the existing shareholders.
2. Proposed resolution to issue warrants without pre-emption rights for the existing shareholders.
3. Proposed resolution to cancel the authorisation set out in clause 5.1 in the Company's current articles of association and replace it with a new authorisation to the board of directors to issue shares without pre-emption rights for the existing shareholders.
4. Proposed resolution to cancel the authorisation set out in clause 5.2 in the Company's current articles of association and replace it with a new authorisation to the board of directors to issue shares with pre-emption rights for the existing shareholders.
5. Proposed resolution to authorise the board of directors to issue warrants without pre-emption rights for the existing shareholders and to increase the Company's share capital in this connection.
6. Proposed resolution to authorise the board of directors to issue warrants with pre-emption rights for the existing shareholders and to increase the Company's share capital in this connection.

Junior Lawyer Michael Kristensen has been appointed chairman of the meeting by the board of directors pursuant to article 11.20 of the Company's Articles of Association.

The chairman of the meeting stated that the meeting will be conducted in English pursuant to article 11.3 of the Articles of Association.

The chairman of the meeting announced that the general meeting had been duly convened, as the notice of the extraordinary general meeting was given on 8 July 2021. The chairman of the meeting described the formal requirements with respect to the notice and concluded that these were met. The chairman of the meeting stated that the maximum number of votes on the general meeting was 20,730,800 votes and that a total of 5,620,450 votes were represented divided between 0 votes by proxy to the Board of Directors and 5,620,450 votes by those shareholders in physical attendance.

The chairman concluded that the general meeting formed a quorum with respect to the agenda.

Re. 1

It was proposed to increase the share capital by up to nominally DKK 63,837.7125 through cash contribution on the terms set out below.

The Company's latest adopted annual report, a report by the Board of Directors and a declaration by the auditor were presented pursuant to section 156 of the Danish Companies Act.

The new shares are offered at market price as at the date of the general meeting, being the closing price (in Danish: lukkekurs) the latest trading day before the general meeting. The closing price the latest trading day before the general meeting is DKK 3.745, so the shares are offered at a price of 9,986.6666 (rounded), equivalent to DKK 3.745 per share.

At the general meeting, it was proposed to set the deadline for payment of the new shares to 30 July 2021 in order for subscribers resident outside of Denmark to be able to transfer the subscription amount in time.

Hence, the terms of the proposed capital increase are as follows:

a. The share capital is increased by minimum nominally DKK 0.0375 and maximum nominally DKK 63,837.7125.

b. The new shares are offered for sale in denominations of DKK 0.0375 and multiples thereof.

c. The new shares are offered without pre-emption rights for the existing shareholders, as the new shares are offered to the following pre-determined persons:
  • Xignotus Capital ApS, CVR-no. 40 23 51 32 (owned by CEO and board member, Jeppe Krog Rasmussen)
  • Magnus Østergaard Dahlmann (board member)
  • Morellco Holding ApS, CVR-no. 32 07 37 35 (owned by CCO John Morell Frellsen)
  • C-Plus Consult, CVR-no. 37 27 78 35 (owned by chairman of the board of directors Carsten Trads)
  • Per Wester (board member)
  • Jinderman & Partners AB, org. no. 559193-1745
  • Kent Ternrud
  • Visima Invest AB, org. no. 559065-4389
  • Marcus Kinnander
  • KCM Invest AB, org. no. 559063-6170
  • Thomas Johansson
  • Carlsen Holding ApS, CVR-no. 39 54 55 78 (owned by board member Christian Carlsen)

d. Each of the above persons must subscribe for such number of shares as is equivalent to the number of warrants such person has subscribed for pursuant to item 2 on the agenda. In the event of any discrepancy between the number of shares and warrants subscribed for by any of the above persons, such person shall be deemed to have subscribed for the lower of such two amounts.

e. The new shares are offered at at a price of 9,986.6666 (rounded), to the effect that DKK 3.745 is paid for each share of nominally DKK 0.0375, equal to payment of a total amount of DKK 6,375,259.555 (if fully subscribed).

f. Subscription for the new shares must be completed no later than four (4) days after the general meeting, i.e. on 27 July 2021.

g. Payment of the new shares must be completed no later than seven (7) days after the general meeting, i.e. on 30 July 2021.

h. Part payment of the new shares is not permitted.

i. The new shares will carry the same rights as the existing shares.

j. The new shares will carry a right of dividend and other rights in the Company from the date of registration of the shares with the Danish Business Authority.

k. The new shares will be registered shares and negotiable instruments.

l. The Company shall pay the costs relating to the capital increase, which are estimated at DKK 30,000 exclusive of VAT.

The proposed resolution and the resulting amendment of the Articles of Association of the Company were passed unanimously with all votes cast.

Upon full subscription of the offered shares, the share capital is nominally DKK 841,242.7125.

Re. 2

It was proposed to issue up to 1,702,339 warrants, each granting the right to subscribe for one (1) share of nominally DKK 0.0375 and to resolve the related capital increase, on the terms set out below.

The Company's latest adopted annual report, a report by the Board of Directors and a declaration by the auditor were presented pursuant to section 156 of the Danish Companies Act.

Each warrant gives the right to subscribe for 1 share of nominally DKK 0.0375 at an exercise price equivalent the subscription price of the shares pursuant to item 1 on the agenda plus 30% (i.e. the market price of the shares as at the date of the extraordinary general meeting plus 30%). The subscription price of the shares pursuant to item 1 on the agenda is DKK 3.745, so each warrant gives the right to subscribe for 1 share of nominally DKK 0.0375 at an exercise price of DKK 4.8685.

The full set of terms of the proposed issue of warrants and the related capital increase are set out in the new Schedule 7.1 to the Company's articles of association (enclosed as Schedule 1 to these minutes) that was presented on the general meeting. The most essential terms of the proposed issue and the related capital increase are as follows:

a. The total number of warrants issued is equivalent to the number of shares issued pursuant to item 1 in the agenda, i.e. minimum 1 and maximum 1,702,339.

b. By exercise of the warrants, the share capital of the Company can increase by minimum nominally DKK 0.0375 and maximum nominally DKK 63,837.7125.

c. The warrants are issued without payment.

d. The warrants are offered without pre-emption rights for the existing shareholders, as the new warrants are offered to the following pre-determined persons:
  • Xignotus Capital ApS, CVR-no. 40 23 51 32 (owned by CEO and board member, Jeppe Krog Rasmussen)
  • Magnus Østergaard Dahlmann (board member)
  • Morellco Holding ApS, CVR-no. 32 07 37 35 (owned by CCO John Morell Frellsen)
  • C-Plus Consult, CVR-no. 37 27 78 35 (owned by chairman of the board of directors Carsten Trads)
  • Per Wester (board member)
  • Jinderman & Partners AB, org. no. 559193-1745
  • Kent Ternrud
  • Visima Invest AB, org. no. 559065-4389
  • Marcus Kinnander
  • KCM Invest AB, org. no. 559063-6170
  • Thomas Johansson
  • Carlsen Holding ApS, CVR-no. 39 54 55 78 (owned by board member Christian Carlsen)

e. Each of the above persons must subscribe for such number of warrants as is equivalent to the number of shares such person has subscribed for pursuant to item 1 on the agenda. In the event of any discrepancy between the number of shares and warrants subscribed for by any of the above persons, such person shall be deemed to have subscribed for the lower of such two amounts.

f. Subscription for the warrants must be completed no later than four (4) days after the general meeting, i.e. on 27 July 2021.

g. Each warrant gives the right to subscribe for 1 share of nominally DKK 0.0375 at an exercise price of DKK 4.8685.

h. The warrants can be exercised in the period 14 July 2022 - 4 August 2022 (as described in the new Schedule 7.1), however see litra (i) below. Hence, in the exercise period the new shares can be subscribed for by exercise of the warrants, and the exercise price in connection with such exercise is payable in this exercise period.

i. In the event of an Exit (as defined in the new Schedule 7.1) or if the Company and a warrant holder so agree, the warrants can be exercised prematurely as set out in clauses 5.3 and 7 in Schedule 7.1.

j. The new shares (subscribed for by exercise of the warrants) will be offered in denominations of nominally DKK 0.0375.

k. The new shares (subscribed for by exercise of the warrants) will carry a right of dividend and other rights in the Company from the date of registration of the shares with the Danish Business Authority.

l. The new shares (subscribed for by exercise of the warrants) will be registered shares and will be registered in the Company's register of shareholders.

m. The new shares (subscribed for by exercise of the warrants) will be negotiable instruments.

n. Part payment of the new shares (subscribed for by exercise of the warrants) is not permitted.
 
o. The new shares (subscribed for by exercise of the warrants) carry the same rights as the existing shares.
 
p. The existing shareholders will not have pre-emptions rights to the shares subscribed for by exercise of the warrants.
 
q. The new shares (subscribed for by exercise of the warrants) will belong to the same share class as the other shares in the Company. If a resolution is made to introduce different share classes in the Company before the issued warrants are exercised, shares subscribed for by exercise of the warrants will belong to the share class which will place the holders in the position as if the issued warrants had been exercised immediately before the introduction of the new share class(es).

r. The Company shall pay the costs relating to the related capital increase, which are estimated at DKK 40,000 exclusive of VAT.

Revised Articles of Association of the Company where the amendment resulting from the proposed resolution is marked up and the new Schedule 7.1 were presented. Adoption of the proposal will imply that the new Schedule 7.1 is attached to Articles of Association and that the following new clause 7.1 is inserted:

"Den 23. juli 2021 "On 23 July 2021, the general meeting resolved to issue
besluttede warrants and to pass a resolution on the potential
generalforsamlingen capital increase related thereto. The issued warrants
at udstede warrants carry the right to subscribe for up to nominally DKK
og traf samtidig [63,837.7125] shares in the Company. The full set of
beslutning om den terms and conditions regarding the warrants are specified
dertil hørende in Schedule 7.1 which forms an integral part of the
potentielle Articles of Association of the Company."
kapitalforhøjelse.
De udstedte
warrants giver ret
til at tegne op til
nominelt
[63.837,7125] kr.
aktier i Selskabet.
De fuldstændige
vilkår for disse
warrants er
indeholdt i Bilag
7.1, der udgør en
integreret del af
Selskabets
vedtægter."

The proposed resolution and the resulting amendment of the Articles of Association of the Company were passed unanimously and with all votes cast.

Re. 3

The board of directors had proposed that the authorisation to the board of directors to issue new shares without pre-emption rights for the existing shareholders as set out in clause 5.1 in the Company's current articles of association is cancelled and replaced by a new authorisation as described below:

It was proposed that the Board of Directors, pursuant to clause 155 of the Danish Companies Act, in the period until 1 June 2026 is authorised to issue shares in the Company and thereby increase the share capital in one or more issues of new shares without pre-emption rights for the Company's existing shareholders by up to a nominal amount of DKK 340,910.

The capital increase can be by way of cash contribution, contribution in kind and/or conversion of debt (to be decided by the board of directors). The capital increase can be below market price. However, if shares are issued to existing shareholders, such issue must be carried out at market price, unless such issue is carried out with pre-emption rights for all existing shareholders.

Shares issued pursuant to this authorisation shall be issued in the name of the holder and registered in the Company's register of shareholders, be fully paid up, be negotiable instruments, there shall be no restrictions on the negotiability of the shares, and the shares shall in every respect carry the same rights as the existing shares.

The board of directors is authorised to lay down the terms and conditions for the capital increases pursuant to the above authorisation and to make such amendments to the Company's articles of association as may be required as a result of the board of directors' exercise of said authorisation.

Further, the total capital increase, which the board of directors can resolve pursuant to this authorisation and the authorisation under item 4 on the agenda collectively, cannot exceed nominally DKK 511,365.

Revised articles of association of the Company where the amendment resulting from the proposed resolution is marked up were presented. Adoption of the proposal will imply that this clause 5.1 in the current articles of association:

"På den ordinære "At the ordinary general meeting held on 28 April 2021,
generalforsamling the Board of Directors was, pursuant to clause 155 of the
den 28. april 2021 Danish Companies Act, in the period until 1 April 2026
blev bestyrelsen i authorized in connection with the Company's potential
henhold til acquisition of shares or assets in another company to
selskabslovens § issue shares in the Company in favour of the seller as
155 i perioden consideration for the acquired shares or assets and
frem til den 1. thereby increase the share capital in one or more issues
april 2026 of new shares without pre-emption rights for the Company's
bemyndiget til i existing shareholders by up to a nominal amount of DKK
forbindelse med 340,910. The capital increase can be by way of
selskabets contribution in kind (by contribution of the shares or
eventuelle assets) and must be at market price based on the average
erhvervelse af closing price the latest 3 weeks up to (but not including)
kapitalandele the date at which the authorisation is exercised. As of
eller aktiver i et the date at which the authorisation is exercised, the
andet selskab at seller, to which the new shares are issued, cannot be (i)
udstede a related party, cf. art. 2 in the Danish Insolvency Act,
kapitalandele i to the Company or to members of the Company's executive
selskabet til management or board of directors or (ii) a shareholder in
sælger som the Company."
vederlag for de
erhvervede
kapitalandele
eller aktiver og
herved foretage én
eller flere
kapitalforhøjelser
i selskabet uden
fortegningsret for
selskabets
eksisterende
kapitalejere med
op til et nominelt
beløb på 340.910
kr.
Kapitalforhøjelse
kan ske ved
apportindskud (ved
indskud af
kapitalandelene
eller aktiverne)
og skal være til
markedskurs
baseret på den
gennemsnitlige
lukkekurs de
seneste 3 uger op
til (men ikke
inklusive) datoen
for udnyttelse af
bemyndigelsen.
Sælger, som
kapitalandelene
udstedes til
fordel for, må på
tidspunktet for
udnyttelse af
bemyndigelsen ikke
være (i)
nærstående, jf.
konkurslovens § 2,
til selskabet
eller medlemmer af
selskabets
direktion eller
bestyrelse eller
(ii) aktionær i
selskabet."

is deleted and replaced by the following new clause 5.1:

"På den "At the extraordinary general meeting held on 23 July
ekstraordinære 2021, the Board of Directors was, pursuant to clause 155
generalforsamling of the Danish Companies Act, in the period until 1 June
den 23. juli 2021 2026 authorised to issue shares in the Company and thereby
blev bestyrelsen i increase the share capital in one or more issues of new
henhold til shares without pre-emption rights for the Company's
selskabslovens § existing shareholders by up to a nominal amount of DKK
155 i perioden 340,910. The capital increase can be by way of cash
frem til den 1. contribution, contribution in kind and/or converision of
juni 2026 debt (to be decided by the Board of Directors). The
bemyndiget til at capital increase can be below market price, however if
udstede shares are issued to existing shareholders, such issue
kapitalandele i must be carried out at market price, unless such issue is
selskabet og carried out with pre-emption rights for all existing
herved foretage shareholders."
kapitalforhøjelser
i selskabet ad en
eller flere gange
uden
fortegningsret for
selskabets
eksisterende
kapitalejere med
op til et nominelt
beløb på 340.910
kr.
Kapitalforhøjelsen
kan ske kontant,
ved apportindskud
og/eller ved
gældskonvertering 
(som besluttes af
bestyrelsen).
Kapitalforhøjelsen
kan ske til under
markedskurs, dog
således at hvis
aktier udstedes
til eksisterende
kapitalejere, skal
sådan udstedelse
ske til
markedkurs, med
mindre udstedelsen
foretages med
fortegningsret for
alle eksisterende
kapitalejere."

Clauses 5.3 and 5.4 shall remain unchanged and shall continue to apply.

The proposed resolution and the resulting amendment of the Articles of Association of the Company were passed unanimously and with all votes cast.

Re. 4

The board of directors had proposed that the authorisation to the board of directors to issue new shares with pre-emption rights for the existing shareholders as set out in clause 5.2 in the Company's current articles of association is cancelled and replaced by a new authorisation as described below:

It was proposed that the board of directors, pursuant to clause 155 of the Danish Companies Act, in the period until 1 June 2026 is authorised to issue shares in the Company and thereby increase the share capital in one or more issues of new shares with pre-emption rights for the Company's existing shareholders by up to a nominal amount of DKK 468,750.

The capital increase can be by way of cash contribution, contribution in kind and/or conversion of debt (to be decided by the board of directors) and can be below market price.

Shares issued pursuant to this authorisation shall be issued in the name of the holder and registered in the Company's register of shareholders, be fully paid up, be negotiable instruments, there shall be no restrictions on the negotiability of the shares, and the shares shall in every respect carry the same rights as the existing shares.

The board of directors is authorised to lay down the terms and conditions for the capital increases pursuant to the above authorisation and to make such amendments to the Company's articles of association as may be required as a result of the board of directors' exercise of said authorisation.

Further, the total capital increase, which the board of directors can resolve pursuant to this authorisation and the authorisation under item 3 on the agenda collectively, cannot exceed nominally DKK 511,365.

Revised Articles of Association of the Company where the amendment resulting from the proposed resolution is marked up were presented. Adoption of the proposal will imply that this clause 5.2 in the current articles of association:

"På den ordinære "At the ordinary general meeting held on 28 April 2021, the
generalforsamling Board of Directors was, pursuant to clause 155 of the
den 28. april Danish Companies Act, in the period until 1 April 2026
2021 blev authorized to increase the share capital in one or more
bestyrelsen i issues of new shares with pre-emption rights for the
henhold til Company's existing shareholders by up to a nominal amount
selskabslovens § of DKK 340,910. The capital increase shall be by way of
155 i perioden cash contribution and can be below market price, whereas
frem til den 1. market price is based on the average closing price the
april 2026 latest 3 weeks up to (but not including) the date at which
bemyndiget til ad the authorisation is exercised."
en eller flere  
gange at forhøje
selskabets
aktiekapital ved
udstedelse af nye
aktier med
fortegningsret
for selskabets
eksisterende
kapitalejere med
op til et
nominelt beløb på
340.910 kr.
Kapitalforhøjelse
skal ske ved
kontant betaling
og kan være til
under
markedskurs, hvor
markedskursen
baseres på den
gennemsnitlige
lukkekurs de
seneste 3 uger op
til (men ikke
inklusive) datoen
for udnyttelse af
bemyndigelsen."

is deleted and replaced by this new clause 5.2:

"På den "At the extraordinary general meeting held on 23 July
ekstraordinære 2021, the Board of Directors was, pursuant to clause 155
generalforsamling of the Danish Companies Act, in the period until 1 June
den 23. juli 2021 2026 authorised to issue shares in the Company and thereby
blev bestyrelsen i increase the share capital in one or more issues of new
henhold til shares with pre-emption rights for the Company's existing
selskabslovens § shareholders by up to a nominal amount of DKK 468,750. The
155 i perioden capital increase can be by way of cash contribution,
frem til den 1. contribution in kind and/or conversion of debt (to be
juni 2026 decided by the Board of Directors) and can be below market
bemyndiget til at price."
udstede
kapitalandele i
selskabet og
herved foretage
kapitalforhøjelser
i selskabet ad en
eller flere gange
med fortegningsret
for selskabets
eksisterende
kapitalejere med
op til et nominelt
beløb på 468.750
kr.
Kapitalforhøjelsen
kan ske kontant,
ved apportindskud
og/eller ved
gældskonvertering
(som besluttes af
bestyrelsen) og
kan være til under
markedskurs."

Clauses 5.3 and 5.4 shall remain unchanged and shall continue to apply.

The proposed resolution and the resulting amendment of the articles of association of the Company were passed unanimously and with all votes cast.

Re. 5

The board of directors had proposed to authorise the board of directors in one or more tranches and in the period until 1 June 2026 to issue warrants granting the right to subscribe for up to 3,750,000 shares of nominally DKK 0.0375, i.e. up to a total of nominally DKK 140,625 shares in the Company, and to authorise the board of directors to resolve the related capital increase.

The warrants can be issued without pre-emption rights for the existing shareholders. The warrants can be issued below market price. However, if warrants are issued to existing shareholders, the subscription price upon exercise of warrants issued must be as a minimum equivalent the market price of the shares as at the date of the issue, unless such issue is carried out with pre-emption rights for all existing shareholders.

Shares that are subscribed for on the basis of warrants issued pursuant to this autorization shall be issued in the name of the holder and registered in the Company's register of shareholders, be fully paid up, be negotiable instruments, there shall be no restrictions on the negotiability of the shares, and the shares shall in every respect carry the same rights as the existing shares.

It was further proposed to authorise the Board of Directors to lay down the more specific conditions for the distribution and issuance of the said warrants.

Revised Articles of Association of the Company where the amendment resulting from the proposed resolution is marked up were presented. Adoption of the proposal will imply that the following new clause 6.5 is inserted in the articles of association:

"På den ekstraordinære "At the extraordinary general meeting held on 23 July
generalforsamling den 2021, the Board of Directors was, pursuant to article
23. juli 2021 blev 169 and to article 155 of the Danish Companies Act,
selskabets bestyrelse i in the period until 1 June 2026 authorized in one or
henhold til more tranches to issue warrants granting the right to
selskabslovens § 169, subscribe for up to 3,750,000 shares of nominally DKK
jf. § 155, i perioden 0.0375, i.e. up to a total of nominally DKK 140,625
frem til den 1. juni shares in the Company. The Board of Directors is at
2026 bemyndiget til ad the same general meeting authorized to resolve the
en eller flere gange at related capital increase. Said warrants can be issued
udstede warrants, der without pre-emption rights for the Company's existing
giver ret til tegning shareholders. The warrants can be issued below market
af op til 3.750.000 price. However, if warrants are issued to existing
stk. aktier a 0,0375 shareholders, the subscription price upon exercise of
kr., dvs. op til i alt warrants must be as a minimum equivalent to the
nominelt 140.625 kr. market price of the shares as at the date of the
aktier. Bestyrelsen er issue, unless the issue is carried out with pre
samtidig bemyndiget til -emption rights for all existing shareholders. The
at foretage den dertil Board of Directors lays down otherwise the more
hørende specific conditions for the distribution and issuance
kapitalforhøjelse. De of the said warrants."
pågældende warrants kan
udstedes uden
fortegningsret for de
eksisterende
kapitalejere. De
pågældende warrants kan
udstedes til under
markedskurs, dog
således at såfremt
warrants udstedes til
eksisterende
kapitalejere, skal
tegningskursen ved
udnyttelse af warrants
mindst svare til
aktiernes markedskurs

udstedelsestidspunktet,
med mindre udstedelsen
sker med fortegningsret
for alle eksisterende
kapitalejere.
Bestyrelsen fastsætter
i øvrigt de nærmere
vilkår for fordelingen
og udstedelsen af de
pågældende warrants."

and that clause 6.6 (previously clause 6.4) is revised as follows:

"Kapitalandele "Shares that are subscribed for on the basis of warrants
tegnet på baggrund issued pursuant to articles 6.1, 6.2, 6.3, 6.4 and 6.5
af warrants shall be issued in the name of the holder and registered
udstedt i medfør in the Company's register of shareholders, be fully paid
af punkt 6.1, 6.2, up, be negotiable instruments, there shall be no
6.3, 6.4 og 6.5 restrictions on the negotiability of the shares, and the
skal lyde på navn shares shall in every respect carry the same rights as the
og noteres i existing shares."
selskabets
ejerbog,
indbetales fuldt
ud, være
omsætningspapirer,
der skal ikke
gælde
begrænsningerne i
kapitalandelenes
omsættelighed, og
de skal i enhver
henseende have
samme rettigheder
som de
eksisterende
kapitalandele."

The proposed resolution and the resulting amendment of the Articles of Association of the Company were passed unanimously and with all votes cast.

Re. 6

The board of directors had proposed to authorise the board of directors in one or more tranches and in the period until 1 June 2026 to issue warrants granting the right to subscribe for up to 9,375,000 shares of nominally DKK 0.0375, i.e. up to a total of nominally DKK 351,562.50 shares in the Company, and to authorize the board of directors to resolve the related capital increase.

The warrants shall be issued with pre-emption rights for the existing shareholders. The warrants can be issued below market price.

Shares that are subscribed for on the basis of warrants issued pursuant to this autorization shall be issued in the name of the holder and registered in the Company's register of shareholders, be fully paid up, be negotiable instruments, there shall be no restrictions on the negotiability of the shares, and the shares shall in every respect carry the same rights as the existing shares.

It was further proposed to authorise the board of directors to lay down the more specific conditions for the distribution and issuance of the said warrants.

Revised Articles of Association of the Company where the amendment resulting from the proposed resolution is marked up were presented. Adoption of the proposal will imply that the following new clause 6.4 is inserted in the Articles of Association:

"På den "At the extraordinary general meeting held on 23 July
ekstraordinære 2021, the Board of Directors was, pursuant to article 169
generalforsamling and to article 155 of the Danish Companies Act, in the
den 23. juli 2021 period until 1 June 2026 authorised in one or more
blev selskabets tranches to issue warrants granting the right to subscribe
bestyrelse i for up to 9,375,000 shares of nominally DKK 0.0375, i.e.
henhold til up to a total of nominally DKK 351,562.50 shares in the
selskabslovens § Company. The Board of Directors is at the same general
169, jf. § 155, i meeting authorized to resolve the related capital
perioden frem til increase. Said warrants must be issued with pre-emption
den 1. juni 2026 rights for the Company's existing shareholders. The
bemyndiget til ad warrants can be issued below market price. The Board of
en eller flere Directors lays down otherwise the more specific conditions
gange at udstede for the distribution and issuance of the said warrants."
warrants, der
giver ret til
tegning af op til
9.375.000 stk.
aktier a 0,0375
kr., dvs. op til i
alt nominelt
351.562,50 kr.
aktier.
Bestyrelsen er
samtidig
bemyndiget til at
foretage den
dertil hørende
kapitalforhøjelse.
De pågældende
warrants skal
udstedes med
fortegningsret for
de eksisterende
kapitalejere. De
pågældende
warrants kan
udstedes til under
markedskurs.
Bestyrelsen
fastsætter i
øvrigt de nærmere
vilkår for
fordelingen og
udstedelsen af de
pågældende
warrants."

and that clause 6.6 (previously clause 6.4) is revised as follows:

"Kapitalandele "Shares that are subscribed for on the basis of warrants
tegnet på baggrund issued pursuant to articles 6.1, 6.2, 6.3, 6.4 and 6.5
af warrants shall be issued in the name of the holder and registered
udstedt i medfør in the Company's register of shareholders, be fully paid
af punkt 6.1, 6.2, up, be negotiable instruments, there shall be no
6.3, 6.4 og 6.5 restrictions on the negotiability of the shares, and the
skal lyde på navn shares shall in every respect carry the same rights as the
og noteres i existing shares."
selskabets
ejerbog,
indbetales fuldt
ud, være
omsætningspapirer,
der skal ikke
gælde
begrænsningerne i
kapitalandelenes
omsættelighed, og
de skal i enhver
henseende have
samme rettigheder
som de
eksisterende
kapitalandele."

The proposed resolution and the resulting amendment of the articles of association of the Company were passed unanimously and with all votes cast.

________

The general meeting authorised Junior Lawyer Michael Kristensen to register the resolutions passed with the Danish Business Authority and in that connection Michael Kristensen was authorised to make any corrections, additions and/or changes to the resolutions required by the Danish Business Authority for registration.

The meeting was closed.